title: CYP2A6 overexpression in human lung cancers correlates with a high malignant status.
abstract: CYP2A6 is a major phase I enzyme metabolizing tobacco-specific nitrosamines, implicated as risk factors for lung cancer. In this study, immunohistochemistry and in situ hybridization (ISH) for CYP2A6 with human lung cancer tissues (n=31) obtained by surgical resection showed significantly higher immunoreactivity in the cases with lymph node metastasis. The adenocarcinoma cases (n=23) with lymph node metastasis or large tumor size showed a high immunoreactivity for CYP2A6. The squamous cell carcinoma cases (n=6) with large tumor size showed a tendency for low CYP2A6 immunoreactivity. ISH for CYP2A6 revealed mRNA expression in both adenocarcinoma and squamous cell carcinoma cells. The data suggest that CYP2A6 could have an important role in the development and proliferation of lung carcinomas. With adenocarcinomas, CYP2A6 could be a target candidate for therapeutic and chemopreventive intervention.
authors.affiliation: Onco-Pathology, Department of Pathology and Host-Defense, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa 761-0793, Japan.
authors.forename: Yoko
authors.initials: Y
authors.lastname: Matsuda
authors.forename: Keiko
authors.initials: K
authors.lastname: Yamakawa
authors.forename: Kousuke
authors.initials: K
authors.lastname: Saoo
authors.forename: Kyoko
authors.initials: K
authors.lastname: Hosokawa
authors.forename: Masanao
authors.initials: M
authors.lastname: Yokohira
authors.forename: Toshiya
authors.initials: T
authors.lastname: Kuno
authors.forename: Junko
authors.initials: J
authors.lastname: Iwai
authors.forename: Takatoshi
authors.initials: T
authors.lastname: Shirai
authors.forename: Kaoru
authors.initials: K
authors.lastname: Obika
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Kamataki
authors.forename: Katsumi
authors.initials: K
authors.lastname: Imaida
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology / Q000556:secondary; D000368:Aged; D001189:Aryl Hydrocarbon Hydroxylases / Q000378:metabolism*; D018287:Carcinoma, Large Cell / Q000201:enzymology / Q000556:secondary; D018288:Carcinoma, Small Cell / Q000201:enzymology / Q000556:secondary; D002294:Carcinoma, Squamous Cell / Q000201:enzymology / Q000556:secondary; D065637:Cytochrome P-450 CYP2A6; D018450:Disease Progression; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008175:Lung Neoplasms / Q000201:enzymology* / Q000473:pathology; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D006899:Mixed Function Oxygenases / Q000378:metabolism*; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis
chemical_list: D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C585710:CYP2A6 protein, human; D065637:Cytochrome P-450 CYP2A6